OncoMatch/Clinical Trials/NCT07030517
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Is NCT07030517 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Teclistamab for multiple myeloma.
Treatment: Teclistamab — The purpose of this study is to assess the safety of teclistamab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma (RRMM) (that is, a blood cancer that comes back after treatment or does not respond to treatment) who have previously received at least 3 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation (CD)38 antibody (is a protein that fights infection) and whose disease have progressed on the last therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
received at least 3 prior lines of therapy including a proteasome inhibitor
Must have received: anti-CD38 antibody
received at least 3 prior lines of therapy including ... an anti-CD 38 antibody
Must have received: immunomodulatory agent
received at least 3 prior lines of therapy including ... an immunomodulatory agent
Cannot have received: BCMA-directed therapy
Received any prior B cell maturation antigen (BCMA)-directed therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify